Related Experiment Video
Updated: Aug 7, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
The $5 Billion Hop: Glatiramer Acetate and the US Patent System
Neeraj G Patel1, Aaron S Kesselheim2,3
1YALE SCHOOL OF MEDICINE, NEW HAVEN, CT, USA.
Abstract:
New research and a government investigation have shed light on an anticompetitive practice called "Product Hopping" and specifically how it was employed in the case of the multiple sclerosis treatment glatiramer acetate beginning in 2014, which cost payers billions of dollars. We examine this case as well as a separate, impending instance of product hopping.
Related Concept Videos
Drug Nomenclature
Drug Regulation
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Phase II Reactions: Glucuronidation
Drug Metabolism: Phase II Reactions
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

